We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2008 by Asociación para Evitar la Ceguera en México.
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00599820
First Posted: January 24, 2008
Last Update Posted: January 24, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Asociación para Evitar la Ceguera en México
  Purpose
Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks

Condition Intervention Phase
Angioid Streaks Choroidal Neovascularization Drug: Intravitreal Bevacizumab Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: OCT, Visual Outcome and Angiographic Analysis of Choroidal Neovascularization in Six Eyes With Angioid Streaks Treated With a Single Intravitreal Injection of Bevacizumab

Resource links provided by NLM:


Further study details as provided by Asociación para Evitar la Ceguera en México:

Primary Outcome Measures:
  • BCVA
  • Fluoresceine Angiography
  • Optical Coherence Tomography

Study Start Date: November 2005
Estimated Study Completion Date: May 2006
Detailed Description:
A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of Angioid Streaks
  • Choroidal neovascularization associated
  • Untreated patients or patients treated once with PDT

Exclusion Criteria:

  • Ocular surgery excepting uncomplicated phacoemulsification
  • Glaucoma or any other ocular pathology
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00599820


Locations
Mexico
Asociación para Evitar la Ceguera en México (APEC)
México city, Distrito Federal, Mexico, 04030
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Investigators
Principal Investigator: Adriana Solís-Vivanco, MD Asociación para Evitar la Ceguera en México
Study Chair: Jans Fromow-Guerra, MD PhD Asociación para Evitar la Ceguera en México
Study Chair: Mariana Martínez-Castellanos, MD Asociación para Evitar la Ceguera en México
Study Chair: Elizabeth Reyna-Castelán, MD Asociación para Evitar la Ceguera en México
Study Chair: Myriam Hernández-Rojas, MD Asociación para Evitar la Ceguera en México
Study Chair: Griselda Alvarez-Rivera, MD Asociación para Evitar la Ceguera en México
Study Director: Hugo Quiroz-Mercado, MD Asociación para Evitar la Ceguera en México
  More Information

ClinicalTrials.gov Identifier: NCT00599820     History of Changes
Other Study ID Numbers: APEC 010
First Submitted: June 30, 2006
First Posted: January 24, 2008
Last Update Posted: January 24, 2008
Last Verified: January 2008

Keywords provided by Asociación para Evitar la Ceguera en México:
Angioid Streaks
Choroidal Neovascularization
Bevacizumab

Additional relevant MeSH terms:
Neovascularization, Pathologic
Choroidal Neovascularization
Angioid Streaks
Metaplasia
Pathologic Processes
Choroid Diseases
Uveal Diseases
Eye Diseases
Retinal Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents